By 2024, ten drugs based on ASOs have been approved by the FDA: mipomersen (treatment for familial hypercholesterolemia), nusinersen (for spinal muscular atrophy), inotersen (for hereditary transthyretin amyloidosis), eplonersen (for polyneuropathy of hereditary transthyretin amyloidosis (ATTR)), milasen (a personalized drug for a disease with CLN7 mutations) [78], eteplirsen (Figure 5B), torfersen (for ALS), and golodirsen, viltolarsen [132], and casimersen [29] (for DMD) (Figure 5C). Here, MFSD8 is linked to Familial transthyretin-related amyloidosis.